Publications by authors named "Gregory Busse"

Claim this Profile
M
Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, Lanyi Xie, Gregory D Busse

J Pharmacokinet Pharmacodyn· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
Azmi Nasser, Roberto Gomeni, Gianpiera Ceresoli-Borroni, Lanyi Xie, Gregory D Busse

J Pharmacokinet Pharmacodyn· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex Metabolism of the Novel Neurosteroid, Ganaxolone, in Humans: A Unique Challenge for Metabolites in Safety Testing Assessment.
William L Fitch, Steven Smith, Michael Saporito, Gregory Busse, Mingbao Zhang

Drug Metab Dispos· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response of peer relations and social activities to treatment with viloxazine extended-release capsules (Qelbree ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention-deficit/hyperactivity disorder.
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, Gregory D Busse, Brendan Lujan

Brain Behav· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder.
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, Gregory D Busse, Zare Melyan

Eur Child Adolesc Psychiatry· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, Soumya A Chaturvedi, Gregory D Busse

Psychiatry Res· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder.
Azmi Nasser, Roberto Gomeni, Zhao Wang, Joseph T Hull, Gregory D Busse

Br J Clin Pharmacol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T Hull, Gregory D Busse

J Clin Psychopharmacol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials.
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, Gregory D Busse, Zare Melyan

Paediatr Drugs· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder.
Azmi Nasser, Alisa R Kosheleff, Joseph T Hull, Tesfaye Liranso, Peibing Qin, Gregory D Busse

Int J Clin Pract· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
Azmi Nasser, Joseph T Hull, Tesfaye Liranso, Gregory D Busse, Zare Melyan

Neuropsychiatr Dis Treat· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
Azmi Nasser, Alisa R Kosheleff, Joseph T Hull, Tesfaye Liranso, Peibing Qin, Gregory D Busse

J Child Adolesc Psychopharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T Hull, Gregory D Busse

Clin Ther· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T Hull, Gregory D Busse

Psychopharmacol Bull· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials.
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, Gregory D Busse, Zare Melyan

Psychiatry Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults.
Azmi Nasser, Shamia L Faison, Tesfaye Liranso, Toyin Adewole, Gregory D Busse

J Clin Psychiatry· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, Nicholas Fry, Joseph T Hull, Gregory D Busse

Clin Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of nicotine on ethanol-induced conditioned taste aversions in Long-Evans rats.
Jennifer A Rinker, Gregory D Busse, Peter G Roma, Scott A Chen, Christina S Barr

Psychopharmacology (Berl)· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An assessment of sex differences in nicotine-induced conditioned taste aversions.
Jennifer A Rinker, Gregory D Busse, Anthony L Riley

Pharmacol Biochem Behav· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strain-dependent sex differences in the effects of alcohol on cocaine-induced taste aversions.
Jermaine D Jones, Gregory D Busse, Anthony L Riley

Pharmacol Biochem Behav· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of cocaine, alcohol and cocaine/alcohol combinations in conditioned taste aversion learning.
Gregory D Busse, Andrey Verendeev, Jermaine Jones, Anthony L Riley

Pharmacol Biochem Behav· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The interaction of sex and route of drug administration in cocaine-induced conditioned taste aversions.
Gregory D Busse, Kevin B Freeman, Anthony L Riley

Pharmacol Biochem Behav· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of alcohol preexposure on cocaine, alcohol and cocaine/alcohol place conditioning.
Gregory D Busse, Elizabeth T Lawrence, Anthony L Riley

Pharmacol Biochem Behav· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cocaine, but not alcohol, reinstates cocaine-induced place preferences.
Gregory D Busse, Anthony L Riley

Pharmacol Biochem Behav· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The modulation of cocaine-induced conditioned place preferences by alcohol: effects of cocaine dose.
Gregory D Busse, Elizabeth T Lawrence, Anthony L Riley

Prog Neuropsychopharmacol Biol Psychiatry· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis